Invention:
This technology consists of a bioengineered cardiac tissue that exhibits electrocardiogram parameters and can be used in screening cardiotoxicity and proarrhythmic potential.
Background:
Currently, pharmaceutical compounds must be screened for cardiotoxicity using in vitro testing and animal models. However, current cell-based methods rely on cell sheets or cell monolayers and predominately focus on one protein or ion channel and do not provide a holistic view of effects on the heart. This technology provides an engineered human cardiac tissue that has clinical parameters that can be used for a more accurate assessment of cardiotoxicity of preclinical drug compounds.
Applications:
- Drug testing
- Cardiotoxicity testing
Advantages:
- Allows for measurement of electrocardiogram activity
- Allows for collection of QT interval data
